Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 16/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6415620 | 0.99 | CCR2 (0.49) | CCR2HTR1AHTR1DHTR2BCCR5 | |
| SCHEMBL6409505 | 0.88 | LMNA (0.47) | HTR1AHTR1DHTR2BCCR5LMNA | |
| SCHEMBL6409109 | 0.87 | CCR2 (0.49) | CCR2CCR5 | |
| SCHEMBL6410259 | 0.87 | HTR2B (0.53) | HTR1AHTR1DHTR2BCCR5LMNA | |
| SCHEMBL6416009 | 0.87 | CCR2 (0.48) | CCR2CCR5 | |
| Hydrochloric Acid SCHEMBL6411483 | 0.87 | LMNA (0.46) | HTR1AHTR1DHTR2BCCR5LMNA | |
| Hydrochloric Acid SCHEMBL6412802 | 0.86 | CCR2 (0.48) | CCR2CCR5 | |
| Hydrochloric Acid SCHEMBL6411467 | 0.86 | HTR2B (0.52) | HTR1AHTR1DHTR2BCCR5LMNA | |
| SCHEMBL6418522 | 0.85 | CCR5 (0.48) | CCR2CCR5 | |
| SCHEMBL5251327 | 0.85 | CCR2 (0.48) | CCR2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | CCR2 5/4885HTR1A 1039/4885HTR1D 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.